Key result
Study evaluates PPI co-prescription impact on GI bleeding and ischemic events in AMI patients on DAPT.
Why the study?
A discrepancy exists between European and American guideline recommendations regarding routine proton pump inhibitor use in patients treated with DAPT.
Does the co-prescription of proton pump inhibitors (PPIs) reduce major gastrointestinal bleeding or affect MACCE in patients with acute myocardial infarction undergoing PCI treated with DAPT?
Cohort
Yes
Does the co-prescription of proton pump inhibitors (PPIs) reduce major gastrointestinal bleeding or affect MACCE in patients with acute myocardial infarction undergoing PCI treated with DAPT?
Observational data leave net effects of PPI co-prescription on GI bleeding and MACCE unresolved in AMI patients on DAPT; randomized trials required.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2025) conducted a cohort in Acute myocardial infarction (AMI) undergoing PCI with DAPT. Proton pump inhibitors (PPIs) vs. No PPI co-prescription was evaluated on Major gastrointestinal bleeding requiring transfusion with hospitalisation within 1 year. The study evaluated the association between PPI co-prescription and gastrointestinal bleeding or ischaemic events in AMI patients on DAPT, but quantitative results were truncated in the abstract.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: